According to a new market research report Biopsy Devices Market
by Product (Core Needle Biopsy, Aspiration Biopsy, Vacuum Assisted
Biopsy) Application (Breast Biopsy, Lung Biopsy, Prostate Biopsy)
Guidance (Stereotactic, Ultrasound) & by End User (Hospital) -
Global Forecast to 2022, published by MarketsandMarkets™, the market is
expected to reach USD 2.42 Billion by 2022 from an estimated USD 1.74
Billion in 2017, at a CAGR of 6.8% during the forecast period.
Browse 180 Market Data Tables and 42 Figures spread through 219 Pages and in-depth TOC on "Biopsy Devices Market"
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=132886515
The
Report analyzes and studies the major market drivers, restraints, and
opportunities in North America, Europe, Asia-Pacific, Latin America, and
the Middle East & Africa.
Factors such as rising prevalence
of cancer, increasing preference for minimally invasive surgeries, and
initiatives undertaken by governments & global health organizations
are the major factors driving the growth of this market.
By product, the needle-based biopsy instruments segment accounted for the largest share of the market
On
the basis of product, the needle-based biopsy instruments segment
accounted for the largest share of the global biopsy devices market in
2016. This can be attributed to the preference of needle-based biopsies
over open surgical biopsies and increasing preference for minimally
invasive surgeries.
The lung biopsy segment is expected to highest growth during the forecast period
Based
on application, the lung biopsy segment accounted for the largest share
of the biopsy devices market. The growing prevalence of lung cancer
will drive market growth. Additionally, the availability of funding for
lung cancer research is contributing to the growth of this market
segment.
The ultrasound-guided biopsy segment dominated the market in 2016
Based
on guidance technique, the ultrasound-guided biopsy segment accounted
for the largest share of the biopsy devices market. This quick and
simple procedure offers advantages, such as no ionizing radiation
exposure, low complication rate, and lower cost as compared to other
biopsy techniques.
The hospitals segment held the highest CAGR during the forecast period
Based
on end user, the hospitals segment is expected to register the highest
growth rate during the forecast period. The strong financial
capabilities of hospitals and the presence of trained professionals are
the major factors supporting the rising adoption of biopsy devices among
hospitals.
North America dominated the market in 2016
North
America accounted for the largest share of the biopsy devices market in
2016, followed by Europe. The rising prevalence of cancer, government
initiatives to spread awareness about cancer, favorable reimbursement
scenario for biopsy devices in the U.S., and the presence of key players
in the region are the key factors driving the growth of the biopsy
devices market in North America.
Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515
The
major players in the biopsy devices market are C. R. Bard, Inc. (U.S.),
Becton, Dickinson and Company (U.S.), Cook Group Incorporated (U.S.),
Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon
Medical Devices (U.S.), B. Braun Melsungen AG (Germany), Cardinal
Health, Inc. (U.S.), Olympus Corporation (Japan), Boston Scientific
Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), INRAD, Inc.
(U.S.), and Medtronic plc (Ireland).
About MarketsandMarkets™
MarketsandMarkets™
provides quantified B2B research on 30,000 high growth niche
opportunities/threats which will impact 70% to 80% of worldwide
companies’ revenues. Currently servicing 7500 customers worldwide
including 80% of global Fortune 1000 companies as clients. Almost 75,000
top officers across eight industries worldwide approach
MarketsandMarkets™ for their painpoints around revenues decisions.
Our
850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global
high growth markets following the “Growth Engagement Model – GEM”. The
GEM aims at proactive collaboration with the clients to identify new
opportunities, identify most important customers, write “Attack, avoid
and defend” strategies, identify sources of incremental revenues for
both the company and its competitors. MarketsandMarkets™ now coming up
with 1,500 MicroQuadrants (Positioning top players across leaders,
emerging companies, innovators, strategic players) annually in high
growth emerging segments. MarketsandMarkets™ is determined to benefit
more than 10,000 companies this year for their revenue planning and help
them take their innovations/disruptions early to the market by
providing them research ahead of the curve.
MarketsandMarkets’s
flagship competitive intelligence and market research platform,
“Knowledge Store” connects over 200,000 markets and entire value chains
for deeper understanding of the unmet insights along with market sizing
and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/biopsy-device.asp
Showing posts with label Biopsy Devices Market. Show all posts
Showing posts with label Biopsy Devices Market. Show all posts
Tuesday, October 19, 2021
Biopsy Devices Market Worth 2.42 Billion USD by 2022
Wednesday, December 11, 2019
Biopsy Devices Market Top Players and Growth Strategies | Industry Report 2022
According to research report the biopsy devices market is expected to reach USD 2.42 billion by 2022 from USD 1.74 billion in 2017, at a CAGR of 6.8% from 2017 to 2022.
The report analyzes the global biopsy devices market by product, guidance technique, application, end user, and region. Based on product, the global market is segmented into needle-based biopsy instruments, procedure trays, localization wires, and other products (forceps, markers, probes, punches, curettes, and sutures). In 2016, the needle-based biopsy instruments segment accounted for the largest share of global market mainly due to the increasing preference for minimally invasive surgeries and higher preference for needle-based biopsies over open surgical biopsies.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132886515
Based on application, the global market is segmented into breast biopsy, lung biopsy, colorectal biopsy, prostate biopsy, and others. The breast biopsy segment accounted for the largest share of the global market in 2016. The rising prevalence of breast cancer and growing awareness about the disease are driving market growth in this segment.
Based on guidance technique, the biopsy devices market is segmented into ultrasound-guided biopsy, stereotactic-guided biopsy, magnetic resonance imaging (MRI)-guided biopsy, and other guidance techniques (positron emission tomography, fluoroscopy, and thermography). In 2016, the ultrasound biopsy segment dominated the market.
Based on end user, the market is segmented into hospitals, diagnostic & imaging centers, and academic & research institutes. In 2016, hospitals formed the largest end-user segment of the market. This can be attributed to the growth in the healthcare sector in emerging economies along with the increase in the out-of-pocket healthcare expenditure and increase in the number of hospitals.
Players in the global biopsy devices market, such as Becton, Dickinson and Company (U.S.), Devicor Medical Products, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), Cardinal Health, Inc. (U.S.), and Boston Scientific Corporation (U.S.) are focusing on increasing their presence in the high-growth markets through agreements, expansions, and acquisitions. Olympus Corporation (Japan), Cook Group Incorporated (U.S.), and Boston Scientific Corporation (U.S.) are some of the players focusing on organic growth strategy of new product launches to enhance their market presence.
C. R. Bard dominated the market due to its broad biopsy devices product portfolio. It operates in around 100 countries outside the U.S. The company manufactures medical devices in the field of vascular therapy, urology, oncology, and surgical specialties. C. R. Bard has a wide product portfolio for biopsy, including vacuum-assisted devices, core needle biopsy products, localization wires, breast tissue markers, and probes.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515
Becton, Dickinson and Company is another prominent player in the market. The company is engaged in the development, manufacturing, and marketing of medical devices, instrument systems, and reagents. BD operates through two business segments—BD Medical and BD Life Sciences. The company offers biopsy products through its medication and procedural solutions segment, which operates under its Medical division.
The report analyzes the global biopsy devices market by product, guidance technique, application, end user, and region. Based on product, the global market is segmented into needle-based biopsy instruments, procedure trays, localization wires, and other products (forceps, markers, probes, punches, curettes, and sutures). In 2016, the needle-based biopsy instruments segment accounted for the largest share of global market mainly due to the increasing preference for minimally invasive surgeries and higher preference for needle-based biopsies over open surgical biopsies.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132886515
Based on application, the global market is segmented into breast biopsy, lung biopsy, colorectal biopsy, prostate biopsy, and others. The breast biopsy segment accounted for the largest share of the global market in 2016. The rising prevalence of breast cancer and growing awareness about the disease are driving market growth in this segment.
Based on guidance technique, the biopsy devices market is segmented into ultrasound-guided biopsy, stereotactic-guided biopsy, magnetic resonance imaging (MRI)-guided biopsy, and other guidance techniques (positron emission tomography, fluoroscopy, and thermography). In 2016, the ultrasound biopsy segment dominated the market.
Based on end user, the market is segmented into hospitals, diagnostic & imaging centers, and academic & research institutes. In 2016, hospitals formed the largest end-user segment of the market. This can be attributed to the growth in the healthcare sector in emerging economies along with the increase in the out-of-pocket healthcare expenditure and increase in the number of hospitals.
Players in the global biopsy devices market, such as Becton, Dickinson and Company (U.S.), Devicor Medical Products, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), Cardinal Health, Inc. (U.S.), and Boston Scientific Corporation (U.S.) are focusing on increasing their presence in the high-growth markets through agreements, expansions, and acquisitions. Olympus Corporation (Japan), Cook Group Incorporated (U.S.), and Boston Scientific Corporation (U.S.) are some of the players focusing on organic growth strategy of new product launches to enhance their market presence.
C. R. Bard dominated the market due to its broad biopsy devices product portfolio. It operates in around 100 countries outside the U.S. The company manufactures medical devices in the field of vascular therapy, urology, oncology, and surgical specialties. C. R. Bard has a wide product portfolio for biopsy, including vacuum-assisted devices, core needle biopsy products, localization wires, breast tissue markers, and probes.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515
Becton, Dickinson and Company is another prominent player in the market. The company is engaged in the development, manufacturing, and marketing of medical devices, instrument systems, and reagents. BD operates through two business segments—BD Medical and BD Life Sciences. The company offers biopsy products through its medication and procedural solutions segment, which operates under its Medical division.
Thursday, February 7, 2019
Rising Prevalence of Cancer Driving the Growth of Biopsy Devices Market
According to the new market research report Biopsy Devices Market by Product (Core Needle Biopsy, Aspiration Biopsy, Vacuum Assisted Biopsy) Application (Breast Biopsy, Lung Biopsy, Prostate Biopsy) Guidance (Stereotactic, Ultrasound) & by End User (Hospital) – Global Forecast to 2022″, published by MarketsandMarkets™, the market is expected to reach USD 2.42 Billion by 2022 from an estimated USD 1.74 Billion in 2017, at a CAGR of 6.8% during the forecast period.
Factors such as rising prevalence of cancer, increasing preference for minimally invasive surgeries, and initiatives undertaken by governments & global health organizations are the major factors driving the growth of this market.
By product, the needle-based biopsy instruments segment accounted for the largest share of the market
On the basis of product, the needle-based biopsy instruments segment accounted for the largest share of the global biopsy devices market in 2016. This can be attributed to the preference of needle-based biopsies over open surgical biopsies and increasing preference for minimally invasive surgeries.
The lung biopsy segment is expected to highest growth during the forecast period
Based on application, the lung biopsy segment accounted for the largest share of the biopsy devices market. The growing prevalence of lung cancer will drive market growth. Additionally, the availability of funding for lung cancer research is contributing to the growth of this market segment.
The ultrasound-guided biopsy segment dominated the market in 2016
Based on guidance technique, the ultrasound-guided biopsy segment accounted for the largest share of the biopsy devices market. This quick and simple procedure offers advantages, such as no ionizing radiation exposure, low complication rate, and lower cost as compared to other biopsy techniques.
The hospitals segment held the highest CAGR during the forecast period
Based on end user, the hospitals segment is expected to register the highest growth rate during the forecast period. The strong financial capabilities of hospitals and the presence of trained professionals are the major factors supporting the rising adoption of biopsy devices among hospitals.
North America accounted for the largest share of the biopsy devices market in 2016, followed by Europe. The rising prevalence of cancer, government initiatives to spread awareness about cancer, favorable reimbursement scenario for biopsy devices in the U.S., and the presence of key players in the region are the key factors driving the growth of the biopsy devices market in North America.
The major players in the Biopsy Devices Market are C. R. Bard, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Cook Group Incorporated (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon Medical Devices (U.S.), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (U.S.), Olympus Corporation (Japan), Boston Scientific Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), INRAD, Inc. (U.S.), and Medtronic plc (Ireland).
Subscribe to:
Posts (Atom)